GENENTA SCIENCE SPA
🇮🇹Italy
- Country
- 🇮🇹Italy
- Ownership
- Public
- Established
- 2014-01-01
- Employees
- 14
- Market Cap
- $74.3M
- Website
- http://www.genenta.com
Nivolumab Plus Chemotherapy Extends Survival in Lymph Node–Only Metastatic Urothelial Cancer
Nivolumab plus gemcitabine/cisplatin chemotherapy significantly improved response rates, overall survival, and progression-free survival in patients with lymph node–only metastatic urothelial carcinoma, according to a post hoc analysis of the CheckMate 901 trial presented at the 2024 ASCO Annual Meeting.
© Copyright 2024. All Rights Reserved by MedPath